G
Giuseppe Palmieri
Researcher at National Research Council
Publications - 286
Citations - 18058
Giuseppe Palmieri is an academic researcher from National Research Council. The author has contributed to research in topics: Melanoma & Cancer. The author has an hindex of 41, co-authored 265 publications receiving 16236 citations. Previous affiliations of Giuseppe Palmieri include Qatar Airways & The Catholic University of America.
Papers
More filters
Journal ArticleDOI
Mutations of the BRAF gene in human cancer
Helen Davies,Graham R. Bignell,Charles Cox,Philip J. Stephens,Sarah Edkins,S. M. Clegg,Jon W. Teague,Hayley Woffendin,Mathew J. Garnett,William Bottomley,Neil Davis,Ed Dicks,Rebecca Ewing,Yvonne Floyd,Kristian Gray,S. Hall,Rachel Hawes,Jaime Hughes,Vivian Kosmidou,Andrew Menzies,Catherine Mould,Adrian Parker,Claire Stevens,Stephen Watt,Steven Hooper,Rebecca Wilson,Hiran Jayatilake,Barry A. Gusterson,Colin Cooper,Janet Shipley,Darren Hargrave,Kathy Pritchard-Jones,Norman J. Maitland,Georgia Chenevix-Trench,Gregory J. Riggins,Darell D. Bigner,Giuseppe Palmieri,Antonio Cossu,Adrienne M. Flanagan,Andrew G. Nicholson,Judy W. C. Ho,Suet Yi Leung,Siu Tsan Yuen,Barbara L. Weber,Hilliard F. Seigler,Timothy L. Darrow,Hugh Paterson,Richard Marais,Christopher J. Marshall,Richard Wooster,Michael R. Stratton,P. Andrew Futreal +51 more
TL;DR: BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers, with a single substitution (V599E) accounting for 80%.
Journal ArticleDOI
The role of BRAF V600 mutation in melanoma
Paolo A. Ascierto,John M. Kirkwood,Jean-Jacques Grob,Ester Simeone,Antonio M. Grimaldi,Michele Maio,Giuseppe Palmieri,Alessandro Testori,Francesco M. Marincola,Nicola Mozzillo +9 more
TL;DR: The first selective inhibitor of mutant BRAF, vemurafenib, after highly encouraging results of the phase I and II trial, was compared to dacarbazine in a phase III trial in treatment-naïve patients (BRIM-3) and showed a relative reduction in risk of death and risk of tumor progression.
Journal ArticleDOI
BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
Maria Colombino,Mariaelena Capone,Amelia Lissia,Antonio Cossu,Corrado Rubino,Vincenzo De Giorgi,Daniela Massi,Ester Fonsatti,Stefania Staibano,Oscar Nappi,Elena Pagani,Milena Casula,Antonella Manca,MariaCristina Sini,Renato Franco,Gerardo Botti,Corrado Caracò,Nicola Mozzillo,Paolo A. Ascierto,Giuseppe Palmieri +19 more
TL;DR: The findings about the prevalence of BRAF/NRAS/p16CDKN2A mutations in paired tumor lesions from patients with melanoma may be useful in the management of this disease.
Journal ArticleDOI
Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.
Antonio M. Grimaldi,Ester Simeone,Diana Giannarelli,Paolo Muto,Sara Falivene,Valentina Borzillo,Francesca Maria Giugliano,Fabio Sandomenico,Antonella Petrillo,Marcello Curvietto,Assunta Esposito,Miriam Paone,Marco Palla,Giuseppe Palmieri,Corrado Caracò,Gennaro Ciliberto,Nicola Mozzillo,Paolo A. Ascierto +17 more
TL;DR: RT after ipilimumab may lead to abscopal responses in some patients with advanced melanoma correlating with prolonged OS, and it is suggested that local responses to RT may be predictive of abscopy responses.
Journal ArticleDOI
Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
Mariaelena Capone,Diana Giannarelli,Domenico Mallardo,Gabriele Madonna,Lucia Festino,Antonio M. Grimaldi,Vito Vanella,Ester Simeone,Miriam Paone,Giuseppe Palmieri,Ernesta Cavalcanti,Corrado Caracò,Paolo A. Ascierto +12 more
TL;DR: Both Neutrophil-to-lymphocyte ratio (NLR) and derived (d) NLR were associated with improved survival when baseline levels were lower than cut-off values, and NLR and dNLR are simple, inexpensive and readily available biomarkers that could be used to help predict response to immunotherapy in patients with advanced melanoma.